The global Immunomodulators Market is
expected to reach USD 233.7 billion by 2025, according to a new study by Grand
View Research, Inc. The market is anticipated to be predominantly driven by
high R&D investments employed by the prominent companies, resulting into
the large-scale production of new and therapeutically advanced drugs. This is
believed to widen the influx of drugs at an unprecedented rate into the
immunomodulators market hence providing highly efficacious treatment
alternatives for numerous autoimmune and inflammatory diseases.
In addition, increasing drugs resistance
is predicted to be responsible for boosting the clinical urgency to develop
potentially new generation immunomodulators with targeted therapy mechanisms.
The aforementioned factors cumulatively are expected to present significant
growth opportunities over the forecast period.
Furthermore, burgeoning
presence of the key players is expected to promote the awareness levels
pertaining to benefits of immunomodulators amongst the patients as well as the
physicians. This is further expected to widen the immunomodulators industry
growth potential during the forecast period.
In addition, increasing
adoption of monoclonal antibodies for a wide range of indications, such as,
multiple sclerosis, Crohn’s disease, rheumatoid arthritis, and Non-Hodgkin’s
Lymphoma, which is expected to boost immunomodulators industry over the
forecast period. The consistent number of product approvals of highly
significant monoclonal antibodies in autoimmune diseases is predicted to be
responsible for widening the scope of growth.
Further Key Findings From the Study Suggest:
- Immunosuppressant held the largest share of the
product segment in 2015, owing to increasing number of transplantation
procedures and need to prevent organ rejection
- Antibodies held the dominant share of
immunosuppressant in 2015, owing to extensive utilization in kidney,
liver, heart, and lung transplants resulting in greater revenue generation
- Immunostimulants expected to grow lucratively
as a result of lower influx of immunostimulant generics for application in
HIV, cancer and multiple sclerosis
- In 2015, North America dominated the global
immunomodulators market owing to presence of wide number of established
pharmaceutical companies involved in extensive commercialization
- The prominent participants are undertaking
research and clinical collaborative strategies to yield new drugs and
thereby to gain competitive advantage
- For instance, in March 2015, Novartis AG
entered into research collaboration with Aduro Biotech. This was carried
out to enhance its next generation cancer immunotherapy product pipeline
No comments:
Post a Comment